Trial
NCT00977067
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Solid Cancers
Intervention
GDC-0152
Why stopped
The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-21